AI assistant
DBV Technologies — Capital/Financing Update 2021
Jan 29, 2021
1248_iss_2021-01-29_75b7211a-ff09-4e53-8460-78995d087d8a.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
As of December 31, 2020, the following assets appeared on the liquidity account:
- 112,302 DBV Technologies shares;
- € 229,086.53.
Upon signing the liquidity contract in July 2018, the following resources appeared on the liquidity account:
- 24,313 DBV Technologies ordinary shares;
- € 682,454.94.
Number of transactions executed during the second half-year of 2020:
- Purchase: 1,180
- Sale: 1,136
Over the same period, the volumes traded represented:
- 517,291 DBV Technologies ordinary shares purchased for €2,005,858.40
- 458,090 DBV Technologies ordinary shares sold for €1,841,496.60
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company's ordinary
shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations Contact
Anne Pollak DBV Technologies +1 857-529-2363 [email protected]
Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]